K. Kaku, S. Inoue, O. Matsuoka
May 1, 2013
Citations
7
Influential Citations
128
Citations
Quality indicators
Journal
Diabetes
Abstract
Dapagliflozin is a selective sodium‐glucose co‐transporter 2 (SGLT2) inhibitor under development as a treatment for type 2 diabetes mellitus (T2DM). This study assessed the efficacy and safety of dapagliflozin monotherapy in Japanese T2DM patients with inadequate glycaemic control.